Errin (Norethindrone) Patent Expiration, LOE Window & CMS Spending
Errin (Norethindrone) by Mayne In: Off-Patent Genericized (AB Competition), 18 AB generics, $931K 2024 CMS Part D & Medicaid spend.
| Regulatory & Reimbursement Dimension | Verified Value |
|---|---|
| Consolidated Sponsor | Mayne In |
| FDA Application & Pathway | Reconciled (UNLINKED) |
| Exclusivity / Cliff Horizon | Off-Patent Genericized (AB Competition) |
| Core Active-Ingredient LOE Date | Not listed / N/A |
| Last Listed Patent or Exclusivity Date | Not listed / N/A |
| Orange Book Patents (*PED Extensions) | 0 patents (0 *PED) |
| Active AB-Rated Generic Competitors | 18 |
| 2024 CMS Total Public Spend | $931K |
| 2024 Medicare Part D Spend | $113K |
| 2024 Medicaid Spend | $818K |
| Reported Wholesale Price Change (CA SB 17) | 0 statutory filings in 2023 to 2026 panel |